Asceniv market forecast points to steady growth through 2026

The Business Research Company says the Asceniv market is expanding as demand rises for immunoglobulin therapies used in primary immunodeficiency and respiratory disease care. North America led the market in 2025, while Asia-Pacific is expected to grow fastest during the forecast period.

Why it matters: - The Asceniv market is tied to treatment demand for patients with immune deficiencies and respiratory conditions. - Growth in this segment can affect how hospitals, specialty clinics and home-infusion providers deliver long-term immunoglobulin therapy. - The report points to rising diagnosis rates and broader treatment access as the main forces shaping future demand.

What happened: - The Business Research Company released a market report on Asceniv, an immunoglobulin (human) injection. - The report covers market growth, segments, regional outlook and key competitors. - The analysis says North America was the largest Asceniv market in 2025. - The analysis says Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report includes regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample is available here. - The full report is available here.

The details: - Asceniv is designed to supply antibodies that help protect against infections. - The therapy is primarily prescribed for people with primary humoral immunodeficiency, a condition in which the body does not produce enough antibodies. - The report says historical growth has been supported by the effectiveness of IVIG therapies, wider recognition of primary immunodeficiency and hospital adoption of immunoglobulin infusions. - The report identifies rising primary immunodeficiency diagnosis rates as a future growth driver. - The report says a shift toward home infusion treatment should support demand. - Better plasma supply management is also listed as a growth factor. - The report says growth in specialized immunology services will help expand the market. - Better adherence to long-term therapy is another demand driver. - Forecast trends include greater use of immunoglobulin replacement therapies, broader diagnosis of primary immunodeficiency disorders, extended antibody infusion treatments, growing acceptance of home-based immunotherapy and improved infection control in immunocompromised patients. - The report says respiratory disease prevalence is a major driver because immunoglobulin treatment can help patients with immune deficiencies and viral respiratory infections. - The report cites a National Institutes of Health projection from December 2023 that US COPD cases could rise by 112 million to 592 million by 2050, equal to 9.5% of the population. - The report says rising immunodeficiency disease prevalence is another growth driver. - The report cites UK Health Security Agency data showing HIV diagnoses in England rose 51% from 3,975 in 2022 to 6,008 in 2023, including cases diagnosed abroad.

Between the lines: - The report frames Asceniv demand as part of a broader shift toward chronic immune support rather than short-term treatment only. - Home infusion and better plasma supply management suggest the market is moving toward more distributed and operationally flexible care models. - The regional split implies mature demand in North America and faster adoption potential in newer or less saturated markets.

What's next: - The report expects continued expansion as primary immunodeficiency detection improves and treatment options broaden. - Market attention will likely stay focused on home infusion, immunoglobulin replacement therapy and infection prevention in immunocompromised patients. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables.